From Wikipedia, the free encyclopedia
Jump to: navigation, search

NRX-1074 is a selective partial agonist of the glycine site of the NMDA receptor which is under development by Naurex for the treatment of major depressive disorder (MDD).[1][2][3] Its mechanism of action and effects are similar to those of GLYX-13 – which is under development as an adjunctive therapy for treatment-resistant depression also by Naurex – but NRX-1074 is several thousand times more potent by weight and, unlike GLYX-13, is orally-active.[2] NRX-1074 has shown rapid antidepressant effects in preclinical models of depression.[2] In addition, similarly to GLYX-13, it is well-tolerated, and lacks the schizophrenia-like psychotomimetic effects of the NMDA receptor antagonist ketamine.[2]

As of May 2014, NRX-1074 is in phase IIa clinical trials for MDD.[2]

See also[edit]


  1. ^ PR Newswire (2010). "Naurex's Novel Antidepressant GLYX-13 Recognized as One of Windhover's Top 10 Neuroscience Projects to Watch". 
  2. ^ a b c d e PR Newswire (2014). "Naurex Reports Positive Top-Line Phase 2b Results for Novel Antidepressant GLYX-13 and Advances NRX-1074 into Phase 2 Depression Study". 
  3. ^ Dang YH, Ma XC, Zhang JC, et al. (January 2014). "Targeting of NMDA Receptors in the Treatment of Major Depression". Curr. Pharm. Des. PMID 24410564. 

External links[edit]